Ionis Pharmaceuticals $IONS

Health Care · NASDAQ

$26.58
-0.64 (-2.35%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 21, 2026, the first target we tracked for IONS.

Ionis Pharmaceuticals (IONS) is trading down at $26.58 (-2.35%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

Analyst price targets on IONS

Current price targets from 2 firms average $60, ranging from $54 to $66 — 126% above the current $26.6. Each is tracked to its date and scored the same way a member's call is.

2 targets, newest first. Open a row for its source and scoring.

DateNov 9, 2026 FirmRaymond James RatingOutperform · lowers Targetat $39.4 · $54 +37% Horizonby Nov 2027 StatusOpen

Entry price $39.4, the close nearest Nov 9, 2026, when the target was reported; the target is +37% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 9, 2027.

Source Raymond James cuts Ionis Pharmaceuticals price target on slow launch Investing.com · Nov 9, 2026 · opens the publisher's site
Raymond James lowered its price target on Ionis Pharmaceuticals stock to $54 from $79 while maintaining an Outperform rating.
DateOct 21, 2026 FirmBMO Capital Markets RatingOutperform · raises Targetat $44.3 · $66 +49% Horizonby Oct 2027 StatusOpen

Entry price $44.3, the close nearest Oct 21, 2026, when the target was reported; the target is +49% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 21, 2027.

Source BMO upgrades Ionis Pharmaceuticals stock rating on sHTG opportunity Investing.com · Oct 21, 2026 · opens the publisher's site
BMO Capital upgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform on Wednesday and raised its price target to $66 from $54.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Ionis Pharmaceuticals revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$1.12B$334.4M−$453.9MFY2016 revenue: $372.8MFY2016 net income: −$60.4M · Net margin −16.2%'16FY2017 revenue: $514.2MFY2017 net income: $346.0K · Net margin 0.1%'17FY2018 revenue: $599.7MFY2018 net income: $273.7M · Net margin 45.6%'18FY2019 revenue: $1.12BFY2019 net income: $278.1M · Net margin 24.8%'19FY2020 revenue: $729.3MFY2020 net income: −$444.3M · Net margin −60.9%'20FY2021 revenue: $810.5MFY2021 net income: −$28.6M · Net margin −3.5%'21FY2022 revenue: $587.4MFY2022 net income: −$269.7M · Net margin −45.9%'22FY2023 revenue: $787.6MFY2023 net income: −$366.3M · Net margin −46.5%'23FY2024 revenue: $705.1MFY2024 net income: −$453.9M · Net margin −64.4%'24FY2025 revenue: $943.7MFY2025 net income: −$381.4M · Net margin −40.4%'25−40.4%0%50%100%FY2016 net margin: −16.2%FY2017 net margin: 0.1%FY2018 net margin: 45.6%FY2019 net margin: 24.8%FY2020 net margin: −60.9% (off the scale, which stops at −40.4%)FY2021 net margin: −3.5%FY2022 net margin: −45.9% (off the scale, which stops at −40.4%)FY2023 net margin: −46.5% (off the scale, which stops at −40.4%)FY2024 net margin: −64.4% (off the scale, which stops at −40.4%)FY2025 net margin: −40.4%
Ionis Pharmaceuticals annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$372.8M$514.2M$599.7M$1.12B$729.3M$810.5M$587.4M$787.6M$705.1M$943.7M
Growth (year over year)+31.4%+37.9%+16.6%+87.2%−35.0%+11.1%−27.5%+34.1%−10.5%+33.8%
Gross profit$372.8M$514.2M$597.9M$1.12B$717.3M$799.6M$573.3M$778.5M$693.9M$927.8M
Gross margin100.0%100.0%99.7%99.6%98.4%98.7%97.6%98.8%98.4%98.3%
Operating income−$20.2M$31.0M−$61.4M$365.9M−$172.1M−$30.2M−$410.2M−$353.7M−$475.1M−$381.7M
Operating margin−5.4%6.0%−10.2%32.6%−23.6%−3.7%−69.8%−44.9%−67.4%−40.4%
Net income−$60.4M$346.0K$273.7M$278.1M−$444.3M−$28.6M−$269.7M−$366.3M−$453.9M−$381.4M
Net margin−16.2%0.1%45.6%24.8%−60.9%−3.5%−45.9%−46.5%−64.4%−40.4%
EPS (diluted)−$0.50$0.15$2.07$1.90−$3.18−$0.20−$1.90−$2.56−$3.04−$2.38
Balance sheet
Cash and equivalents$84.7M$129.6M$278.8M$683.3M$397.7M$869.2M$276.5M$399.3M$242.1M$372.3M
Total assets$912.5M$1.32B$2.67B$3.23B$2.39B$2.61B$2.53B$2.99B$3.00B$3.52B
Total liabilities$812.9M$957.5M$1.48B$1.55B$1.65B$1.84B$1.96B$2.60B$2.42B$3.03B
Long-term debt———$785.5M$539.1M—$1.18B$1.24B$1.20B$1.33B
Shareholders' equity$99.6M$281.0M$1.05B$1.47B$743.3M$771.7M$572.9M$386.7M$588.4M$489.1M
Cash flow
Operating cash flow−$112.1M$174.1M$602.9M$345.6M$35.9M$30.8M−$274.4M−$307.5M−$500.9M−$268.6M
Capital expenditure$7.11M$34.8M$13.6M$30.9M$35.1M$12.0M$15.7M$23.8M$45.3M$51.4M
Free cash flow−$119.2M$139.4M$589.3M$314.7M$772.0K$18.8M−$290.1M−$331.3M−$546.2M−$320.0M
Share buybacks—$0$0$34.4M$90.5M$0$0———

From Ionis Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Ionis Pharmaceuticals in the news

Sep 4, 2026 Yahoo Finance NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

Source: Wikipedia — Ionis Pharmaceuticals

Headquarters
Carlsbad, California From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →